A detailed history of Jt Stratford LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Jt Stratford LLC holds 3,009 shares of REGN stock, worth $2.15 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
3,009
Previous 3,093 2.72%
Holding current value
$2.15 Million
Previous $3.25 Million 2.68%
% of portfolio
0.56%
Previous 0.63%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1024.09 - $1201.76 $86,023 - $100,947
-84 Reduced 2.72%
3,009 $3.16 Million
Q2 2024

Aug 14, 2024

BUY
$883.2 - $1071.19 $996,249 - $1.21 Million
1,128 Added 57.4%
3,093 $3.25 Million
Q1 2024

May 14, 2024

BUY
$902.69 - $993.35 $429,680 - $472,834
476 Added 31.97%
1,965 $1.89 Million
Q4 2023

Feb 14, 2024

BUY
$775.18 - $881.7 $13,953 - $15,870
18 Added 1.22%
1,489 $1.31 Million
Q3 2023

Nov 14, 2023

BUY
$692.45 - $844.37 $264,515 - $322,549
382 Added 35.08%
1,471 $1.21 Million
Q2 2023

Aug 14, 2023

SELL
$700.03 - $830.35 $809,934 - $960,714
-1,157 Reduced 51.51%
1,089 $782,000
Q1 2023

May 10, 2023

BUY
$680.49 - $826.97 $177,607 - $215,839
261 Added 13.15%
2,246 $1.85 Million
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $832,244 - $903,573
1,179 Added 146.28%
1,985 $1.43 Million
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $72,320 - $91,264
-126 Reduced 13.52%
806 $555,000
Q2 2022

Aug 15, 2022

BUY
$548.35 - $738.84 $39,481 - $53,196
72 Added 8.37%
932 $551,000
Q1 2022

May 12, 2022

SELL
$595.12 - $698.43 $159,492 - $187,179
-268 Reduced 23.76%
860 $601,000
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $252,718 - $312,001
465 Added 70.14%
1,128 $712,000
Q3 2021

Nov 15, 2021

BUY
$574.03 - $680.96 $380,581 - $451,476
663 New
663 $401,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Jt Stratford LLC Portfolio

Follow Jt Stratford LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jt Stratford LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jt Stratford LLC with notifications on news.